Government-Owned Inventions; Availability for Licensing, 11846 [2024-03120]
Download as PDF
<![CDATA[
11846
Federal Register / Vol. 89, No. 32 / Thursday, February 15, 2024 / Notices
It is determined that the Cures
Acceleration Network Review Board, is
in the public interest in connection with
the performance of duties imposed on
the National Institutes of Health by law,
and that these duties can best be
performed through the advice and
counsel of this group.
Inquiries may be directed to Claire
Harris, Director, Office of Federal
Advisory Committee Policy, Office of
the Director, National Institutes of
Health, 6701 Democracy Boulevard,
Suite 1000, Bethesda, Maryland 20892
(Mail code 4875), Telephone (301) 496–
2123, or harriscl@mail.nih.gov.
Dated: February 9, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–03110 Filed 2–14–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director; Notice of Charter
Renewal
khammond on DSKJM1Z7X2PROD with NOTICES
In accordance with Title 41 of the
U.S. Code of Federal Regulations,
Section 102–3.65(a), notice is hereby
given that the charter for the National
Center for Advancing Translational
Sciences Advisory Council, was
renewed for an additional two-year
period on February 7, 2024.
It is determined that the National
Center for Advancing Translational
Sciences Advisory Council, is in the
public interest in connection with the
performance of duties imposed on the
National Institutes of Health by law, and
that these duties can best be performed
through the advice and counsel of this
group.
Inquiries may be directed to Claire
Harris, Director, Office of Federal
Advisory Committee Policy, Office of
the Director, National Institutes of
Health, 6701 Democracy Boulevard,
Suite 1000, Bethesda, Maryland 20892
(Mail code 4875), Telephone (301) 496–
2123, or harriscl@mail.nih.gov.
Dated: February 9, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–03104 Filed 2–14–24; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
18:36 Feb 14, 2024
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Daniel Lee at 301–761–6327 or
daniel.lee5@nih.gov. Licensing
information may be obtained by
communicating with the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852; tel. 301–496–
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished information
related to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
SUMMARY:
DeePlexing—Extending Imaging
Multiplexity Using Machine Learning
Description of Technology: Spatial
proteomics and transcriptomics are fastemerging fields with the potential to
revolutionize various branches of
biology. In the last five years, various
multiplex immunofluorescence and
immunohistochemistry imaging
methods have been developed to stain
5–60 different protein markers in a
given tissue. Nonetheless, most of these
techniques are iterative and can image
a maximum of 3–8 markers in a single
cycle, resulting in processing time of
several hours to days.
Scientists at National Institute of
Allergy and Infectious Diseases (NIAID)
and National Cancer Institute (NCI) have
developed a new method—
DeePlexing—that uses a deep learning
algorithm to dramatically enhance the
number of markers stained in a single
imaging cycle. This is accomplished
with no changes or upgrades to the
imaging platform itself. In the
DeePlexing method, multiple
antibodies/probes are conjugated to the
same fluorophores and later
deconvolved computationally to retrieve
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
the multichannel signal with high
accuracy. In digital spatial profiling,
DeePlexing enables the user to detect
seven different protein markers in a
single cycle using only three
fluorophores and even quadruple the
number of markers in a single round
without compromising the quality of
RNA and protein in the sample. For
multiplex protein profiling, DeePlexing
can potentially stain for up to 255
different protein markets with eight
fluorophores and deconvolve the signal
for each of the 255 markers
computationally.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404.
Potential Commercial Applications:
• Imaging platforms in spatial
transcriptomics
• Multiplex protein spatial imaging
Competitive Advantages:
• Enhances the number of markers
stained in a single imaging cycle
• Achieves this marker detection
increase without compromising RNA
or protein quality when that is part of
the analytical pipeline
• Reduces the required processing time
for multiplex imaging platforms
• Inexpensive and replicable
Development Stage:
• Prototype
Inventors: Ronald N. Germain
(NIAID), Spencer M. Grant (NIAID),
Nishant Thakur (NIAID), Chen Zhao
(NCI), and Abigail J. Wong-Rolle (NCI).
Intellectual Property: HHS Reference
No. E–202–2021–0; Software Tool.
Licensing Contact: To license this
technology, please contact Daniel Lee at
301–761–6327 or daniel.lee5@nih.gov,
and reference E–202–2021–0.
Dated: February 9, 2024.
Surekha Vathyam,
Deputy Director,Technology Transfer and
Intellectual Property Office,National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2024–03120 Filed 2–14–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Notice of Meeting for the
Interdepartmental Serious Mental
Illness Coordinating Committee
(ISMICC)
Substance Abuse and Mental
Health Services Administration,
Department of Health and Human
Services.
AGENCY:
E:\FR\FM\15FEN1.SGM
15FEN1
]]>Agencies
[Federal Register Volume 89, Number 32 (Thursday, February 15, 2024)]
[Notices]
[Page 11846]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-03120]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Daniel Lee at 301-761-6327 or
[email protected]. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
DeePlexing--Extending Imaging Multiplexity Using Machine Learning
Description of Technology: Spatial proteomics and transcriptomics
are fast-emerging fields with the potential to revolutionize various
branches of biology. In the last five years, various multiplex
immunofluorescence and immunohistochemistry imaging methods have been
developed to stain 5-60 different protein markers in a given tissue.
Nonetheless, most of these techniques are iterative and can image a
maximum of 3-8 markers in a single cycle, resulting in processing time
of several hours to days.
Scientists at National Institute of Allergy and Infectious Diseases
(NIAID) and National Cancer Institute (NCI) have developed a new
method--DeePlexing--that uses a deep learning algorithm to dramatically
enhance the number of markers stained in a single imaging cycle. This
is accomplished with no changes or upgrades to the imaging platform
itself. In the DeePlexing method, multiple antibodies/probes are
conjugated to the same fluorophores and later deconvolved
computationally to retrieve the multichannel signal with high accuracy.
In digital spatial profiling, DeePlexing enables the user to detect
seven different protein markers in a single cycle using only three
fluorophores and even quadruple the number of markers in a single round
without compromising the quality of RNA and protein in the sample. For
multiplex protein profiling, DeePlexing can potentially stain for up to
255 different protein markets with eight fluorophores and deconvolve
the signal for each of the 255 markers computationally.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
Potential Commercial Applications:
Imaging platforms in spatial transcriptomics
Multiplex protein spatial imaging
Competitive Advantages:
Enhances the number of markers stained in a single imaging
cycle
Achieves this marker detection increase without compromising
RNA or protein quality when that is part of the analytical pipeline
Reduces the required processing time for multiplex imaging
platforms
Inexpensive and replicable
Development Stage:
Prototype
Inventors: Ronald N. Germain (NIAID), Spencer M. Grant (NIAID),
Nishant Thakur (NIAID), Chen Zhao (NCI), and Abigail J. Wong-Rolle
(NCI).
Intellectual Property: HHS Reference No. E-202-2021-0; Software
Tool.
Licensing Contact: To license this technology, please contact
Daniel Lee at 301-761-6327 or [email protected], and reference E-202-
2021-0.
Dated: February 9, 2024.
Surekha Vathyam,
Deputy Director,Technology Transfer and Intellectual Property
Office,National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-03120 Filed 2-14-24; 8:45 am]
BILLING CODE 4140-01-P
